Intense and recurrent déjà vu experiences related to amantadine and phenylpropanolamine in a healthy male

@article{Taiminen2001IntenseAR,
  title={Intense and recurrent d{\'e}j{\`a} vu experiences related to amantadine and phenylpropanolamine in a healthy male},
  author={Tero Taiminen and Satu K. J{\"a}{\"a}skel{\"a}inen},
  journal={Journal of Clinical Neuroscience},
  year={2001},
  volume={8},
  pages={460-462}
}
We report a case of a 39-year-old caucasian healthy male physician who developed intense and recurrent déjà vu experiences within 24h of initiating concomitant amantadine-phenylpropanolamine treatment against influenza. Déjà vu experiences terminated on discontinuation of medication. Findings in temporal epilepsy suggest that mesial temporal structures, including hippocampus, are related to paramnesic symptoms. On the other hand, previous case reports have confirmed that both amantadine and… Expand
Recurring déjà vu associated with 5-hydroxytryptophan
TLDR
An iatrogenic case with implications for the neuropharmacological basis of déjà vu, in which a 42-year-old woman received 5-hydroxytryptophan, in combination with carbidopa, as treatment for palatal tremor, on two occasions, separated by 1 week. Expand
Déjà Vécu: When Groundhog Day Gets Real
Deja vecu is an extremely rare type of identifying paramnesia characterised by the ongoing sensation of having experienced things before. Having the delusional conviction that this sensation is true,Expand
A review of the déjà vu experience.
TLDR
Systematic research is needed on the prevalence and etiology of this culturally familiar cognitive experience, and several laboratory models may help clarify this illusion of recognition. Expand
Neuroimaging and cognitive changes during déjà vu
TLDR
The results confirm the role of mesiotemporal structures in the pathogenesis of DV and hypothesize that individual neuroanatomy and disturbances in gamma oscillations or in the dopaminergic system played a role in DBS-elicited DV in a 22-year-old woman treated with deep brain stimulation for hemidystonia. Expand
Déjà vu experiences in schizophrenia: relations with psychopathology and antipsychotic medication.
TLDR
The decreased frequency of déjà vu experiences in patients with schizophrenia may be mainly due to the negative symptoms, and the positive relation between frequency and dosage of neuroleptics remains uncertain. Expand
The persistence of erroneous familiarity in an epileptic male: Challenging perceptual theories of déjà vu activation
TLDR
Déjà vu is likely to be the result of a cognitive feeling borne of the erroneous activation of neural familiarity circuits such as the parahippocampal gyrus, persisting as long as this activation persists. Expand
The persistence of erroneous familiarity 3 Acknowledgements
We report the case of a 39 year-old, temporal lobe epileptic male, MH. Prior to complex partial seizure, experienced up to three times a day, MH often experiences an aura experienced as a persistentExpand
Temporal Lobe Epilepsy (TLE) , “déjà vu” phenomenon and religious experiences
A LOT OF CONTROVERSIES APPEAR REGARDING TEMPORAL LOBE EPILEPSY TO BRIDGE THE GAP BETWEEN RELIGION AND NEUROSCIENCE. TLE WAS DESCRIBED IN LITERATURE IN 1869 BY RUSSIAN WRITER DOSTOEVSKY (WHO SUFFEREDExpand
Reduplicative Paramnesia: A Review
TLDR
There does appear to be a consensus that RP may have a neurologic rather than psychiatric cause and that right and bifrontal lesions as well as the cognitive dissonance associated with memory, visuospatial and impaired conceptual integration are common factors in RP presentation. Expand
A Review of the DejaVu Experience
For more than a century, the dejavu experience has been examined through retrospective surveys, prospective surveys, and case studies. About 60% of the population has experienced dejavu, and itsExpand
...
1
2
3
...

References

SHOWING 1-10 OF 15 REFERENCES
Phenylpropanolamine-induced psychosis. Potential predisposing factors.
TLDR
A report of paranoid psychosis following use of a decongestant containing PPA is reported and case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines is summarized. Expand
Effect of Amantadine on Sexual Dysfunction in Neuroleptic‐Treated Male Schizophrenic Patients
TLDR
Amantadine may be effective for improving sexual function in male schizophrenic patients receiving neuroleptic medication, according to patients' scores in three out of four areas of sexual function. Expand
Possible use of amantadine in depression.
TLDR
Only a limited body of evidence is available, and further studies are needed to investigate the efficacy of amantadine as well as its modes of action in depression, but an overview of the current data is presented. Expand
Mental side effects of amantadine therapy: its spectrum and characteristics in a normal population.
TLDR
The author does not feel the findings warrant discontinuing the prophylactic usage of amantadine but do highlight the need for physician and patient education about its side effects. Expand
Déjà vu experiences and reduplicative paramnesia.
TLDR
A schizophrenic patient with different forms of experiences of inappropriate familiarity with traumatic experiences as aetiological factors in déjà vu experiences and reduplicative paramnesia is described. Expand
Clinical use of amantadine in brain injury rehabilitation.
TLDR
It is suggested amantadine may play a role in neurobehavioural recovery of brain injury, and the need for more in-depth study is demonstrated. Expand
Episodic Psychic Symptoms in the General Population
TLDR
It is proposed that some subclinical dysfunctions can be associated with the appearance of episodic psychic phenomena in otherwise normal subjects. Expand
Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine
TLDR
Present results are consistent with stimulation of DDC activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine, and suggest that this response is an important mechanism underlying the anti‐parkinsonian properties of amanadine. Expand
Development, Reliability, and Validity of a Dissociation Scale
  • E. Bernstein
  • Psychology, Medicine
  • The Journal of nervous and mental disease
  • 1986
TLDR
The Dissociative Experiences Scale (DES) has been developed to offer a means of reliably measuring dissociation in normal and clinical populations and was able to distinguish between subjects with a dissociative disorder (multiple personality) and all other subjects. Expand
Ventral hippocampal dopamine D1 and D2 systems and spatial working memory in rats
TLDR
Clear evidence is provided that hippocampal D2 activity is positively related to working memory performance, while evidence for D1 systems is less compelling. Expand
...
1
2
...